Bayer’s “Next Wave” Of Products Will Reach Phase III Beachhead By 2015
This article was originally published in The Pink Sheet Daily
In an interview, Bayer HealthCare’s recently-arrived new chief executive Olivier Brandicourt discusses the five assets that most excite the firm.
You may also be interested in...
Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.
France’s Provepharm Life Solutions, which finds new uses for known mature molecules, in particular antidotes and surgical dyes, by improving their efficacy and maximizing their therapeutic potential, has fresh funds to expand its portfolio.
Provention has been working hard collecting necessary data for a potential BLA resubmission for teplizumab in patients at risk of developing type 1 diabetes after receiving a complete response letter in July. Hopes rest on a Type A meeting with the FDA in Q4.